Literature DB >> 6375887

Detection and quantification of mitoxantrone in human organs. A case report.

J Roboz, P A Paciucci, D Silides, J Greaves, J F Holland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6375887     DOI： 10.1007/bf00401451

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  4 in total

1.  Letter: Daunomycin (NSC-82151) and adriamycin (NSC-123127): a hypothesis concerning antitumor activity and cardiotoxicity.

Authors:  R H Adamson
Journal:  Cancer Chemother Rep       Date:  1974 May-Jun

2.  Comparison of the interaction of antineoplastic aminoanthraquinone analogs with DNA using competitive fluorescence polarization.

Authors:  J Roboz; C L Richardson; J F Holland
Journal:  Life Sci       Date:  1982-07-05       Impact factor: 5.037

3.  Competitive fluorescence polarization study of the binding of 1,4-dihydroxy-5,8-bis[(2-[(2-hydroxyethyl) amino] ethyl]amino] 9-10-anthracenedione to DNA.

Authors:  C L Richardson; J Roboz; J F Holland
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1980-03

4.  Mitoxantrone in patients with acute leukemia in relapse.

Authors:  P A Paciucci; T Ohnuma; J Cuttner; R T Silver; J F Holland
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701
  4 in total
  7 in total

1.  Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration.

Authors:  J D Nagel; F J Varossieau; R Dubbelman; W W ten Bokkel Huinink; J G McVie
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Pharmacokinetics and metabolism of mitoxantrone. A review.

Authors:  G Ehninger; U Schuler; B Proksch; K P Zeller; J Blanz
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

3.  Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone.

Authors:  D Baker; J K O'Neill; A N Davison; J L Turk
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

4.  Local hyperthermic treatment does not enhance mitoxantrone effectiveness for responses of a rat solid tumour regrowing after irradiation.

Authors:  C van Bree; E M Schopman; P J Bakker; J B Kipp; G W Barendsen
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

5.  Human central nervous system and plasma pharmacology of mitoxantrone.

Authors:  R M Green; D J Stewart; H Hugenholtz; M T Richard; M Thibault; V Montpetit
Journal:  J Neurooncol       Date:  1988       Impact factor: 4.130

6.  Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice.

Authors:  K M Rentsch; D H Horber; R A Schwendener; H Wunderli-Allenspach; E Hänseler
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation.

Authors:  B Richard; M C Launay-Iliadis; A Iliadis; S Just-Landi; D Blaise; A M Stoppa; P Viens; M H Gaspard; D Maraninchi; J P Cano
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.